The Effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial

Désiŕee Van Der Heijde, Atulya (Atul) Deodhar, Jürgen Braun, Michael Mack, Benjamin Hsu, Timothy A. Gathany, Robert D. Inman, Chenglong Han

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective. To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement, as assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS), and improvements in health-related quality of life (HRQOL) and productivity through 2 years in patients with AS. Methods. In the phase III GO-RAISE trial, 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 (n = 78), golimumab 50 mg (n = 138), or golimumab 100 mg (n = 140) at baseline and every 4 weeks. The proportions of patients with ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score <1.3) were determined. HRQOL was assessed using the 36-item Medical Outcomes Study Short Form-36 physical/mental component summary (SF-36 PCS/MCS) scores (normal score ≥ 50). The effect of disease on productivity was assessed by visual analog scale (0-10). Regression analyses on the association of disease activity and HRQOL were performed. The final assessment was at Week 104. Results. Significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease at weeks 14 and 24 versus placebo. Through Week 104, patients who achieved ASDAS inactive disease or major improvement had significantly greater improvements in SF-36 PCS and MCS scores and productivity than did patients not meeting these targets. Among all patients, achieving ASDAS inactive disease at weeks 52 and 104 was associated with normalized SF-36 PCS/MCS scores and significant improvements in work productivity. Conclusion. Greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease and improved HRQOL versus placebo. Achieving an inactive disease state by ASDAS criteria (<1.3) was associated with normalized HRQOL through 2 years. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)1095-1103
Number of pages9
JournalJournal of Rheumatology
Volume41
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Ankylosing Spondylitis
Quality of Life
Therapeutics
golimumab
Placebos
Rheumatology
Visual Analog Scale

Keywords

  • Ankylosing spondylitis
  • ASDAS
  • Golimumab
  • Health-related quality of life
  • Productivity

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

The Effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis : 2-year results of the GO-RAISE trial. / Van Der Heijde, Désiŕee; Deodhar, Atulya (Atul); Braun, Jürgen; Mack, Michael; Hsu, Benjamin; Gathany, Timothy A.; Inman, Robert D.; Han, Chenglong.

In: Journal of Rheumatology, Vol. 41, No. 6, 2014, p. 1095-1103.

Research output: Contribution to journalArticle

Van Der Heijde, Désiŕee ; Deodhar, Atulya (Atul) ; Braun, Jürgen ; Mack, Michael ; Hsu, Benjamin ; Gathany, Timothy A. ; Inman, Robert D. ; Han, Chenglong. / The Effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis : 2-year results of the GO-RAISE trial. In: Journal of Rheumatology. 2014 ; Vol. 41, No. 6. pp. 1095-1103.
@article{0ce28bfeb4424d518088988636b246f8,
title = "The Effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial",
abstract = "Objective. To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement, as assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS), and improvements in health-related quality of life (HRQOL) and productivity through 2 years in patients with AS. Methods. In the phase III GO-RAISE trial, 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 (n = 78), golimumab 50 mg (n = 138), or golimumab 100 mg (n = 140) at baseline and every 4 weeks. The proportions of patients with ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score <1.3) were determined. HRQOL was assessed using the 36-item Medical Outcomes Study Short Form-36 physical/mental component summary (SF-36 PCS/MCS) scores (normal score ≥ 50). The effect of disease on productivity was assessed by visual analog scale (0-10). Regression analyses on the association of disease activity and HRQOL were performed. The final assessment was at Week 104. Results. Significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease at weeks 14 and 24 versus placebo. Through Week 104, patients who achieved ASDAS inactive disease or major improvement had significantly greater improvements in SF-36 PCS and MCS scores and productivity than did patients not meeting these targets. Among all patients, achieving ASDAS inactive disease at weeks 52 and 104 was associated with normalized SF-36 PCS/MCS scores and significant improvements in work productivity. Conclusion. Greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease and improved HRQOL versus placebo. Achieving an inactive disease state by ASDAS criteria (<1.3) was associated with normalized HRQOL through 2 years. The Journal of Rheumatology",
keywords = "Ankylosing spondylitis, ASDAS, Golimumab, Health-related quality of life, Productivity",
author = "{Van Der Heijde}, D{\'e}siŕee and Deodhar, {Atulya (Atul)} and J{\"u}rgen Braun and Michael Mack and Benjamin Hsu and Gathany, {Timothy A.} and Inman, {Robert D.} and Chenglong Han",
year = "2014",
doi = "10.3899/jrheum.131003",
language = "English (US)",
volume = "41",
pages = "1095--1103",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - The Effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis

T2 - 2-year results of the GO-RAISE trial

AU - Van Der Heijde, Désiŕee

AU - Deodhar, Atulya (Atul)

AU - Braun, Jürgen

AU - Mack, Michael

AU - Hsu, Benjamin

AU - Gathany, Timothy A.

AU - Inman, Robert D.

AU - Han, Chenglong

PY - 2014

Y1 - 2014

N2 - Objective. To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement, as assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS), and improvements in health-related quality of life (HRQOL) and productivity through 2 years in patients with AS. Methods. In the phase III GO-RAISE trial, 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 (n = 78), golimumab 50 mg (n = 138), or golimumab 100 mg (n = 140) at baseline and every 4 weeks. The proportions of patients with ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score <1.3) were determined. HRQOL was assessed using the 36-item Medical Outcomes Study Short Form-36 physical/mental component summary (SF-36 PCS/MCS) scores (normal score ≥ 50). The effect of disease on productivity was assessed by visual analog scale (0-10). Regression analyses on the association of disease activity and HRQOL were performed. The final assessment was at Week 104. Results. Significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease at weeks 14 and 24 versus placebo. Through Week 104, patients who achieved ASDAS inactive disease or major improvement had significantly greater improvements in SF-36 PCS and MCS scores and productivity than did patients not meeting these targets. Among all patients, achieving ASDAS inactive disease at weeks 52 and 104 was associated with normalized SF-36 PCS/MCS scores and significant improvements in work productivity. Conclusion. Greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease and improved HRQOL versus placebo. Achieving an inactive disease state by ASDAS criteria (<1.3) was associated with normalized HRQOL through 2 years. The Journal of Rheumatology

AB - Objective. To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement, as assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS), and improvements in health-related quality of life (HRQOL) and productivity through 2 years in patients with AS. Methods. In the phase III GO-RAISE trial, 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 (n = 78), golimumab 50 mg (n = 138), or golimumab 100 mg (n = 140) at baseline and every 4 weeks. The proportions of patients with ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score <1.3) were determined. HRQOL was assessed using the 36-item Medical Outcomes Study Short Form-36 physical/mental component summary (SF-36 PCS/MCS) scores (normal score ≥ 50). The effect of disease on productivity was assessed by visual analog scale (0-10). Regression analyses on the association of disease activity and HRQOL were performed. The final assessment was at Week 104. Results. Significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease at weeks 14 and 24 versus placebo. Through Week 104, patients who achieved ASDAS inactive disease or major improvement had significantly greater improvements in SF-36 PCS and MCS scores and productivity than did patients not meeting these targets. Among all patients, achieving ASDAS inactive disease at weeks 52 and 104 was associated with normalized SF-36 PCS/MCS scores and significant improvements in work productivity. Conclusion. Greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease and improved HRQOL versus placebo. Achieving an inactive disease state by ASDAS criteria (<1.3) was associated with normalized HRQOL through 2 years. The Journal of Rheumatology

KW - Ankylosing spondylitis

KW - ASDAS

KW - Golimumab

KW - Health-related quality of life

KW - Productivity

UR - http://www.scopus.com/inward/record.url?scp=84901708936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901708936&partnerID=8YFLogxK

U2 - 10.3899/jrheum.131003

DO - 10.3899/jrheum.131003

M3 - Article

C2 - 24737912

AN - SCOPUS:84901708936

VL - 41

SP - 1095

EP - 1103

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -